2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl (2-(4-((4-hydroxyphenyl)(4-methylcyclohexylidene)methyl)phenoxy)ethyl)(methyl)carbamate

ID: ALA5220701

Chembl Id: CHEMBL5220701

PubChem CID: 168298751

Max Phase: Preclinical

Molecular Formula: C42H47NO8

Molecular Weight: 693.84

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OC(=O)N(C)CCOc1ccc(C(=C2CCC(C)CC2)c2ccc(O)cc2)cc1

Standard InChI:  InChI=1S/C42H47NO8/c1-28-7-12-31(13-8-28)40(32-14-18-34(44)19-15-32)33-16-20-35(21-17-33)50-24-23-43(2)42(45)51-37-25-29(11-22-36(37)46-3)9-10-30-26-38(47-4)41(49-6)39(27-30)48-5/h9-11,14-22,25-28,44H,7-8,12-13,23-24H2,1-6H3/b10-9-,40-31-

Standard InChI Key:  JGEZCJWKNXCEOD-WUPUIUNKSA-N

Alternative Forms

  1. Parent:

    ALA5220701

    ---

Associated Targets(Human)

MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR2 Tclin Estrogen receptor beta (9272 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 693.84Molecular Weight (Monoisotopic): 693.3302AlogP: 9.12#Rotatable Bonds: 13
Polar Surface Area: 95.92Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 9.39CX Basic pKa: CX LogP: 8.70CX LogD: 8.70
Aromatic Rings: 4Heavy Atoms: 51QED Weighted: 0.14Np Likeness Score: -0.04

References

1. Guo K, Ma X, Li J, Zhang C, Wu L..  (2022)  Recent advances in combretastatin A-4 codrugs for cancer therapy.,  241  [PMID:35964428] [10.1016/j.ejmech.2022.114660]

Source